Role of cancer stem cell markers ALDH1, BCL11B, BMI-1, and CD44 in the prognosis of advanced HNSCC
ConclusionAlthough validation in independent cohorts is still needed, testing for CSC markers in patients with advanced or late stage HNSCC might be beneficial, especially if many comorbidities exist or disease is irresectable. The findings might guide the development and earlier use of targeted therapies in the future.
Source: Strahlentherapie und Onkologie - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Genital Warts | Head and Neck Cancer | HNSCC | HPV Testing | Human Papillomavirus (HPV) | Skin Cancer | Squamous Cell Carcinoma | Statistics | Stem Cell Therapy | Stem Cells | Study